Plain-English translation of NCT06475118 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is looking for better ways to detect sarcopenia — muscle loss and weakness — in people with hepatocellular carcinoma (liver cancer). Researchers will compare blood tests that measure muscle-related proteins with standard imaging scans to see which method works best at identifying muscle loss. The goal is to find a simpler, faster way to diagnose this condition without requiring repeated CT scans.
Muscle loss is very common in people with liver cancer and cirrhosis, and it makes treatments less effective, increases the risk of serious complications, and worsens quality of life. Right now, doctors rely on CT scans to detect muscle loss, but these scans have limitations — especially in people with liver disease. This study hopes to find reliable blood tests that could diagnose muscle loss more easily and help doctors track how well their patients are doing during treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood drawn to measure specific proteins related to muscle health, and your existing CT scans will be analyzed to measure your muscle mass. The study involves one visit after your liver cancer diagnosis is confirmed, where researchers will collect your blood sample and review your imaging. This is a diagnostic study — you won't be taking a new medication, but rather helping researchers understand which tests work best to detect muscle loss.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
France